טוען...
Study design and clinical evidence in mRCC: Can we save axitinib as a first-line therapy?
Tyrosine kinase inhibitors are de facto the most commonly used targeted therapies for upfront treatment of metastatic renal cell carcinoma (mRCC). After the first era in which targeted agents were compared with placebo and interferon-α, a new phase has started in recent years characterized by head-t...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Landes Bioscience
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4026069/ https://ncbi.nlm.nih.gov/pubmed/24556857 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.28161 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|